Wave Life Sciences Ltd. (WVE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Wave Life Sciences Ltd. (WVE) trades at $5.42 with AI Score 20/100 (Grade F). Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative genetic medicines using stereopure oligonucleotides. Market cap: $1.07B, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 10, 2026WVE stock analysis for 2026: Analysts have set a consensus price target of $34.29 for Wave Life Sciences Ltd., suggesting 533.2% upside from the current price of $5.42. The AI MoonshotScore is 20/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
WVE: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Wave Life Sciences Ltd. (WVE) Healthcare & Pipeline Overview
Wave Life Sciences Ltd. leverages its proprietary PRISM platform to develop stereopure oligonucleotides targeting genetic disorders, positioning itself as a leader in genetic medicine within the competitive biotechnology landscape.
What Is the Investment Thesis for WVE?
Wave Life Sciences Ltd. presents a compelling investment thesis driven by its innovative PRISM platform and a robust pipeline of therapeutic candidates addressing significant unmet medical needs. The company’s market capitalization of $1.07B reflects investor confidence in its potential to deliver groundbreaking treatments for genetic disorders. Key growth catalysts include the advancement of WVE-004 and WVE-003 through clinical trials, with expectations for potential FDA submissions within the next 1-2 years. The company’s strong gross margin of 93.8% indicates efficient production capabilities, while its strategic collaborations with industry leaders provide additional resources and validation. However, the company faces risks such as regulatory hurdles and competition from established players in the biotechnology sector. Overall, Wave Life Sciences is well-positioned to capitalize on growing demand for genetic therapies, with the global biotechnology market projected to reach $2.4 trillion by 2028.
Based on FMP financials and quantitative analysis
WVE Key Highlights
Market capitalization of $1.07B, positioning Wave Life Sciences as a notable player in the biotechnology sector.
- Gross margin of 93.8%, significantly higher than the industry average, indicating strong operational efficiency.
- Profit margin of -255.7%, reflecting the company's investment in R&D as it advances its clinical pipeline.
- Collaboration agreements with major pharmaceutical companies such as Pfizer and Takeda, enhancing its research capabilities.
- A diverse pipeline including multiple candidates in various stages of development targeting serious genetic disorders.
Who Are WVE's Competitors?
WVE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TERN Terns Pharmaceuticals, Inc. | $52.95 | -0.03% | $4.77B | 51 |
| SYRE Spyre Therapeutics, Inc. | $107.79 | -1.04% | $9.36B | — |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
| VERV Verve Therapeutics, Inc. | $11.13 | +0.27% | $994M | 71 |
| CLYM Climb Bio, Inc. | $17.02 | -1.85% | $975M | 76 |
| ABUS Arbutus Biopharma Corporation | $4.77 | -4.22% | $942M | 83 |
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| TBPH Theravance Biopharma, Inc. | $16.99 | +0.24% | $881M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WVE's Key Strengths?
Innovative proprietary platform (PRISM) for drug development.
- Strong gross margins reflecting operational efficiency.
- Diverse pipeline addressing critical unmet medical needs.
What Are WVE's Weaknesses?
High negative profit margin indicating significant R&D expenditures.
- Limited commercialized products currently on the market.
- Dependence on successful clinical trial outcomes.
What Could Drive WVE Stock Higher?
Completion of Phase 1 clinical trials for WVE-004, with results expected in Q4 2026.
- Collaboration with Pfizer Inc. to develop innovative therapies, enhancing research capabilities.
- Initiation of Phase 2 trials for WVE-003 targeting Huntington's disease, anticipated in early 2027.
What Are the Key Risks for WVE?
Negative return on equity (-50.1%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that may delay product approvals.
- Competition from established biotechnology firms with similar therapeutic focuses.
- Market volatility impacting funding and investment opportunities.
What Are the Growth Opportunities for WVE?
- Growth opportunity 1: The development of WVE-004 for ALS and frontotemporal dementia represents a significant market opportunity, as the global ALS market is projected to reach $1.1 billion by 2027. With no current cure available, successful clinical trials could lead to substantial revenue potential for Wave Life Sciences.
- Growth opportunity 2: Wave Life Sciences' WVE-003 targeting Huntington's disease addresses a market valued at approximately $1.6 billion. With the increasing prevalence of this neurodegenerative disorder, the company's innovative approach could position it as a leader in this therapeutic area within the next five years.
- Growth opportunity 3: The development of GalNAc-conjugated AIMers for treating Alpha-1 antitrypsin deficiency (AATD) opens access to a market expected to grow significantly as awareness and diagnosis improve. The AATD market is estimated to reach $1.5 billion by 2026, providing Wave Life Sciences a lucrative avenue for growth.
- Growth opportunity 4: The company's preclinical programs for retinal diseases, including Usher syndrome type 2A and retinitis pigmentosa, target a market projected to exceed $3 billion. With increasing investment in gene therapies for ocular conditions, Wave Life Sciences could capture a significant share of this emerging market.
- Growth opportunity 5: Wave Life Sciences' focus on CNS disorders through multiple preclinical programs positions it well within a rapidly expanding market. The global CNS therapeutics market is expected to reach $150 billion by 2027, driven by the rising prevalence of neurological diseases and the demand for innovative treatments.
What Opportunities Does WVE Have?
- Growing demand for genetic therapies in the biotechnology market.
- Potential for partnerships with larger pharmaceutical companies.
- Expansion into emerging markets for genetic medicine.
What Are WVE's Competitive Advantages?
- Proprietary PRISM platform provides a unique approach to drug development.
- Strong intellectual property portfolio protecting its innovations.
- Established collaborations with major industry players enhance credibility.
- Focused expertise in stereopure oligonucleotides differentiates it from competitors.
- Robust pipeline of candidates targeting high unmet medical needs.
What Does WVE Do?
Wave Life Sciences Ltd. was founded in 2012 and is headquartered in Singapore. The company specializes in the design, optimization, and production of stereopure oligonucleotides, a novel class of therapeutics aimed at addressing genetic diseases. Utilizing its proprietary PRISM platform, Wave Life Sciences develops oligonucleotides that target ribonucleic acid (RNA) to either reduce the expression of harmful proteins or restore the production of functional proteins. The company is currently advancing several key programs, including WVE-004, aimed at treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, and WVE-003, which targets Huntington's disease. Additionally, WVE-N531 focuses on Duchenne muscular dystrophy, while ATXN3 is in discovery stages for spinocerebellar ataxia 3. The company is also developing GalNAc-conjugated AIMers for hepatic conditions such as Alpha-1 antitrypsin deficiency (AATD) and has preclinical programs targeting retinal diseases like Usher syndrome type 2A and retinitis pigmentosa. Wave Life Sciences has established collaboration agreements with notable entities such as Pfizer Inc. and Takeda Pharmaceutical Company, enhancing its research capabilities and market reach. With a dedicated workforce of 287 employees, Wave Life Sciences is poised to make significant contributions to the field of genetic medicine.
What Products and Services Does WVE Offer?
- Develops novel stereopure oligonucleotides for genetic medicine.
- Utilizes the PRISM platform for drug discovery and development.
- Targets RNA to modulate protein expression related to genetic disorders.
- Advances multiple clinical-stage programs for serious neurological diseases.
- Engages in collaborations with leading pharmaceutical companies and academic institutions.
- Focuses on innovative treatments for both CNS and hepatic indications.
How Does WVE Make Money?
- Generates revenue through partnerships and collaborations with pharmaceutical companies.
- Develops proprietary therapeutics targeting specific genetic disorders.
- Invests in R&D to advance clinical trials and bring products to market.
- Explores licensing agreements for its innovative drug candidates.
- Utilizes its proprietary platform to enhance drug development efficiency.
What Industry Does WVE Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in genetic medicine and increasing investment in R&D. The global biotechnology market is expected to expand at a CAGR of 7.4%, reaching approximately $2.4 trillion by 2028. Wave Life Sciences operates within a competitive landscape that includes companies like Terns Pharmaceuticals, Inc. (TERN) and Spyre Therapeutics, Inc. (SYRE), both of which are also focused on innovative therapeutic solutions. As a clinical-stage company, Wave Life Sciences is positioned to capitalize on emerging trends in genetic therapies, particularly in the treatment of rare and complex diseases that have limited treatment options.
Who Are WVE's Key Customers?
- Pharmaceutical companies seeking innovative therapeutic solutions.
- Research institutions collaborating on genetic medicine projects.
- Patients with genetic disorders in need of novel treatments.
- Healthcare providers looking for advanced therapeutic options.
- Investors interested in biotechnology and genetic medicine sectors.
Company Profile
Wave Life Sciences Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Singapore, SG. The company is led by CEO Paul Bolno. WVE has traded publicly since 2015.
Key Financial Metrics
Return on equity for Wave Life Sciences Ltd. stands at -50.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.99 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.8%, the inverse of the P/E and a quick read on earnings relative to price.
WVE Valuation & Market Position
With a $1.07B market cap, Wave Life Sciences Ltd. sits in the small-cap segment of the market. Relative to its peer group, WVE's quantitative score of 20/100 is below the peer average of 67/100.
Quarterly Financial Performance: Wave Life Sciences Ltd.
Revenue for Wave Life Sciences Ltd. came in at $2.3M during Q2 2026, a 94.1% contraction versus the preceding quarter. The company recorded a net loss of $69.4M, with diluted EPS of $-0.34. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, WVE averaged $-0.27 in diluted EPS.
Financial Health
Wave Life Sciences Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.47 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Wave Life Sciences Ltd. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 19.0% above estimates on average.
Forward Outlook
Wall Street analysts project Wave Life Sciences Ltd. revenue of about $53.3M for fiscal 2026, with EPS near $-1.11. The estimate reflects 10 contributing analysts.
WVE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in WVE's long-term prospects, indicating that key stakeholders believe in the company's direction.
- Community sentiment has been increasingly positive, with discussions highlighting potential breakthroughs in their genetic medicines.
- The recent advancements in their clinical trials have sparked optimism, as they may address significant unmet medical needs in rare diseases.
- Market perception is shifting favorably, with analysts acknowledging the innovative approach WVE is taking in gene therapies.
Bear Case
- Concerns over the timeline for clinical trial results have created uncertainty, leading some investors to hesitate on WVE's near-term performance.
- Community discussions reflect skepticism regarding the scalability of their technologies, with doubts about the commercial viability of their products.
- Recent market developments in the biotech sector have raised questions about competition, particularly from larger firms with more resources.
- Insider selling in the past has caused some unease among investors, raising red flags about potential issues within the company's strategy.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $2M | -$69M | -$0.34 |
| Q1 2026 | $38M | -$26M | -$0.13 |
| Q4 2025 | $17M | -$53M | -$0.30 |
| Q3 2025 | $8M | -$54M | -$0.32 |
Based on FMP financials and quantitative analysis
WVE Latest News
No recent news available for WVE.
WVE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WVE.
Price Targets
Consensus target: $34.29
WVE MoonshotScore
What does this score mean?
The MoonshotScore rates WVE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Wave Life Sciences Ltd. Analysis
Leadership: Paul Bolno
CEO
Paul Bolno has over 20 years of experience in the biotechnology and pharmaceutical industries. He holds an M.D. from the University of Pennsylvania and an M.B.A. from the Wharton School. Prior to joining Wave Life Sciences, he served in various leadership roles at notable biotech companies, focusing on strategic development and operational excellence.
Track Record: Under Paul Bolno's leadership, Wave Life Sciences has advanced its clinical pipeline significantly and established key partnerships with major pharmaceutical companies. His strategic vision has positioned the company as a leader in genetic medicine.
WVE Healthcare Stock FAQ
What does the AI Score mean for WVE?
WVE holds an AI Score of 20/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative genetic medicines using stereopure oligonucleotides. The company aims to address critical unmet …
What does Wave Life Sciences Ltd. do?
Wave Life Sciences Ltd. is a clinical-stage biotechnology company that develops innovative genetic medicines using stereopure oligonucleotides. The company focuses on targeting RNA to modulate protein expression related to various genetic disorders, with a robust pipeline addressing diseases such as ALS, Huntington's disease, and Duchenne muscular dystrophy.
What do analysts say about WVE stock?
Analysts view Wave Life Sciences Ltd. as a promising player in the biotechnology sector, particularly due to its innovative approach to genetic medicine. Key valuation metrics highlight a market cap of $1.07B, with expectations for significant growth as clinical trials progress. Analysts emphasize the importance of upcoming trial results in shaping future stock performance.
What are the main risks for WVE?
Wave Life Sciences Ltd. faces several risks, including potential regulatory hurdles that could delay product approvals and commercialization. Additionally, ongoing competition from established biotechnology firms presents challenges in capturing market share. Market volatility may also affect funding opportunities, impacting the company's ability to advance its clinical pipeline.
What are the key factors to evaluate for WVE?
Wave Life Sciences Ltd. (WVE) holds an AI score of 20/100 (low). Analysts target $34.29 (+533%). presents a compelling investment thesis driven by its innovative PRISM platform and a robust pipeline of therapeutic candidates addressing significant unmet medical needs. Not financial advice.
How frequently does WVE data refresh on this page?
WVE's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven WVE's recent stock price performance?
Wave Life Sciences Ltd. (WVE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary platform (PRISM) for drug development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WVE overvalued or undervalued right now?
Wave Life Sciences Ltd. (WVE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $34.29 (+533%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research WVE before investing?
Before investing in Wave Life Sciences Ltd. (WVE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is based on the latest available data and may be subject to change as new developments occur.